

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 February 2025 (13.02.2025)



(10) International Publication Number
WO 2025/034912 A3

(51) International Patent Classification:

A61K 31/4162 (2006.01) *A61K 31/4439* (2006.01)
A61K 31/4155 (2006.01) *A61K 31/444* (2006.01)
A61K 31/4192 (2006.01) *C07D 211/98* (2006.01)
A61K 31/437 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2024/041350

(22) International Filing Date:

07 August 2024 (07.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/517,996	07 August 2023 (07.08.2023)	US
63/590,177	13 October 2023 (13.10.2023)	US
63/614,476	22 December 2023 (22.12.2023)	US

(71) Applicant: **COGENT BIOSCIENCES, INC.** [US/US];
275 Wyman Street, 3rd Floor, Waltham, Massachusetts
02451 (US).

(72) Inventors: **FELL, Jay Bradford**; c/o Cogent Biosciences,
Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado

80301 (US). **ROBINSON, John E.**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **FISCHER, John P.**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **VINE, Logan E.**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **RODRIGUEZ, Martha E.**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **FULTON, Jennifer**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **BETTENDORF, Tanna**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **NEWHOUSE, Bradley J.**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **RIEGER, Robert A.**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **MALINKY, Cori A.**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **SMITH, Aaron Christopher**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **JALLURI, Ravi Kumar**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **CHICARELLI, Mark Joseph**; c/o Cogent Biosciences, Inc., 4840 Pearl E

(54) Title: COMPOUNDS FOR FGFR INHIBITION





FIG. 1



(57) Abstract: A compound having the following structure of Formula (IV): (IV) or a stereoisomer, salt, or tautomer thereof, wherein R₁, R₂, R₃, A, B, X, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.

[Continued on next page]

Circle, Suite 100, Boulder, Colorado 80301 (US). **SALITURO, Leah J.**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **MEJIA, Macedonio J.**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US).

(74) **Agent: KANEKO, Miho** et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts 02210 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

(88) **Date of publication of the international search report:**

30 May 2025 (30.05.2025)

(15) **Information about Correction:**

see Notice of 24 April 2025 (24.04.2025)